Dengue virus

Molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria

Scott B. Halstead, Franz X. Heinz, Alan Barrett, John T. Roehrig

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Multivalent dengue vaccines now in late stage development pose unique vaccine safety challenges in that primary or secondary vaccine failures might place vaccines at risk to antibody-dependent enhanced (ADE) wild-type dengue infections. This conference was organized to address this unique vaccine safety issue. New data were presented on the structure of dengue and other flaviviruses, the cellular receptors of dengue virus for biologically relevant cells, dengue viral cell entry mechanisms and mechanisms underlying in vivo protection, neutralization and enhancement of dengue virus infection. It was concluded that a targeted research program should aim to develop an in vitro test to characterize persons immunized with dengue vaccines as completely or partially protected. Achievement of this aim will require a better understanding of the basic mechanisms by which dengue viruses recognize, attach, enter and infect relevant human cells and how antibodies protect against dengue infections.

Original languageEnglish (US)
Pages (from-to)849-856
Number of pages8
JournalVaccine
Volume23
Issue number7
DOIs
StatePublished - Jan 4 2005

Fingerprint

Dengue virus
Dengue Virus
dengue
Dengue
Austria
Dengue Vaccines
Vaccines
pathogenesis
vaccines
cells
Safety
Flavivirus
Antibodies
Virus Diseases
Infection
Flaviviridae
antibodies
research programs
neutralization
Research

Keywords

  • Antibodies
  • Dengue
  • Vaccine
  • Viral structure

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Dengue virus : Molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria. / Halstead, Scott B.; Heinz, Franz X.; Barrett, Alan; Roehrig, John T.

In: Vaccine, Vol. 23, No. 7, 04.01.2005, p. 849-856.

Research output: Contribution to journalArticle

Halstead, Scott B. ; Heinz, Franz X. ; Barrett, Alan ; Roehrig, John T. / Dengue virus : Molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria. In: Vaccine. 2005 ; Vol. 23, No. 7. pp. 849-856.
@article{6c1fdd30019645c08630dd21c61267d4,
title = "Dengue virus: Molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria",
abstract = "Multivalent dengue vaccines now in late stage development pose unique vaccine safety challenges in that primary or secondary vaccine failures might place vaccines at risk to antibody-dependent enhanced (ADE) wild-type dengue infections. This conference was organized to address this unique vaccine safety issue. New data were presented on the structure of dengue and other flaviviruses, the cellular receptors of dengue virus for biologically relevant cells, dengue viral cell entry mechanisms and mechanisms underlying in vivo protection, neutralization and enhancement of dengue virus infection. It was concluded that a targeted research program should aim to develop an in vitro test to characterize persons immunized with dengue vaccines as completely or partially protected. Achievement of this aim will require a better understanding of the basic mechanisms by which dengue viruses recognize, attach, enter and infect relevant human cells and how antibodies protect against dengue infections.",
keywords = "Antibodies, Dengue, Vaccine, Viral structure",
author = "Halstead, {Scott B.} and Heinz, {Franz X.} and Alan Barrett and Roehrig, {John T.}",
year = "2005",
month = "1",
day = "4",
doi = "10.1016/j.vaccine.2004.03.069",
language = "English (US)",
volume = "23",
pages = "849--856",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "7",

}

TY - JOUR

T1 - Dengue virus

T2 - Molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria

AU - Halstead, Scott B.

AU - Heinz, Franz X.

AU - Barrett, Alan

AU - Roehrig, John T.

PY - 2005/1/4

Y1 - 2005/1/4

N2 - Multivalent dengue vaccines now in late stage development pose unique vaccine safety challenges in that primary or secondary vaccine failures might place vaccines at risk to antibody-dependent enhanced (ADE) wild-type dengue infections. This conference was organized to address this unique vaccine safety issue. New data were presented on the structure of dengue and other flaviviruses, the cellular receptors of dengue virus for biologically relevant cells, dengue viral cell entry mechanisms and mechanisms underlying in vivo protection, neutralization and enhancement of dengue virus infection. It was concluded that a targeted research program should aim to develop an in vitro test to characterize persons immunized with dengue vaccines as completely or partially protected. Achievement of this aim will require a better understanding of the basic mechanisms by which dengue viruses recognize, attach, enter and infect relevant human cells and how antibodies protect against dengue infections.

AB - Multivalent dengue vaccines now in late stage development pose unique vaccine safety challenges in that primary or secondary vaccine failures might place vaccines at risk to antibody-dependent enhanced (ADE) wild-type dengue infections. This conference was organized to address this unique vaccine safety issue. New data were presented on the structure of dengue and other flaviviruses, the cellular receptors of dengue virus for biologically relevant cells, dengue viral cell entry mechanisms and mechanisms underlying in vivo protection, neutralization and enhancement of dengue virus infection. It was concluded that a targeted research program should aim to develop an in vitro test to characterize persons immunized with dengue vaccines as completely or partially protected. Achievement of this aim will require a better understanding of the basic mechanisms by which dengue viruses recognize, attach, enter and infect relevant human cells and how antibodies protect against dengue infections.

KW - Antibodies

KW - Dengue

KW - Vaccine

KW - Viral structure

UR - http://www.scopus.com/inward/record.url?scp=10444256421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10444256421&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2004.03.069

DO - 10.1016/j.vaccine.2004.03.069

M3 - Article

VL - 23

SP - 849

EP - 856

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 7

ER -